ATE198040T1 - Feste fettnanoemulsionen als wirkstoffabgabevehikel - Google Patents

Feste fettnanoemulsionen als wirkstoffabgabevehikel

Info

Publication number
ATE198040T1
ATE198040T1 AT94917967T AT94917967T ATE198040T1 AT E198040 T1 ATE198040 T1 AT E198040T1 AT 94917967 T AT94917967 T AT 94917967T AT 94917967 T AT94917967 T AT 94917967T AT E198040 T1 ATE198040 T1 AT E198040T1
Authority
AT
Austria
Prior art keywords
pct
date nov
drug delivery
delivery vehicles
nanoemulsions
Prior art date
Application number
AT94917967T
Other languages
English (en)
Inventor
Shimon Amselem
Doron Friedman
Original Assignee
Pharmos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmos Corp filed Critical Pharmos Corp
Application granted granted Critical
Publication of ATE198040T1 publication Critical patent/ATE198040T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S428/00—Stock material or miscellaneous articles
    • Y10S428/922—Static electricity metal bleed-off metallic stock
    • Y10S428/9335—Product by special process
    • Y10S428/937—Sprayed metal
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y10S977/917—Vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/918—Immunological
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Preparation (AREA)
  • Fats And Perfumes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT94917967T 1993-05-18 1994-05-16 Feste fettnanoemulsionen als wirkstoffabgabevehikel ATE198040T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/063,613 US5576016A (en) 1993-05-18 1993-05-18 Solid fat nanoemulsions as drug delivery vehicles
PCT/US1994/005330 WO1994026252A1 (en) 1993-05-18 1994-05-16 Solid fat nanoemulsions as drug delivery vehicles

Publications (1)

Publication Number Publication Date
ATE198040T1 true ATE198040T1 (de) 2000-12-15

Family

ID=22050367

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94917967T ATE198040T1 (de) 1993-05-18 1994-05-16 Feste fettnanoemulsionen als wirkstoffabgabevehikel

Country Status (10)

Country Link
US (3) US5576016A (de)
EP (1) EP0702552B1 (de)
JP (1) JP3626184B2 (de)
AT (1) ATE198040T1 (de)
AU (2) AU676921B2 (de)
CA (1) CA2162993C (de)
DE (1) DE69426418T2 (de)
IL (1) IL109641A (de)
SG (1) SG106029A1 (de)
WO (2) WO1994026252A1 (de)

Families Citing this family (291)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL101241A (en) * 1992-03-16 1997-11-20 Yissum Res Dev Co Pharmaceutical or cosmetic composition comprising stabilized oil-in-water type emulsion as carrier
DE4244122C1 (de) * 1992-12-24 1994-06-01 Sanol Arznei Schwarz Gmbh Lyophilisierte, wirkstoffhaltige Emulsion zur intravenösen Applikation
AU686149B2 (en) * 1993-04-19 1998-02-05 Institute For Advanced Skin Research Inc. Microemulsion preparation containing difficultly absorbable substance
ES2070076B1 (es) * 1993-04-20 1996-04-16 Cusi Lab Metodo para aumentar la estabilidad de las nanocapsulas durante su almacenamiento.
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US20020099067A1 (en) * 1993-07-08 2002-07-25 Ulrich Posanski Pharmaceutical compositions for sparingly soluble therapeutic agents
IL106578A (en) * 1993-08-03 2000-08-13 Yissum Res Dev Co Pharmaceutical compositions for drug targeting
FR2709666B1 (fr) * 1993-09-07 1995-10-13 Oreal Composition cosmétique ou dermatologique constituée d'une émulsion huile dans eau à base de globules huileux pourvus d'un enrobage cristal liquide lamellaire.
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
US5672358A (en) * 1994-06-21 1997-09-30 Ascent Pharmaceuticals, Inc. Controlled release aqueous emulsion
JPH0827018A (ja) * 1994-07-22 1996-01-30 Sanwa Kagaku Kenkyusho Co Ltd 生理活性ペプチド又は蛋白質を含有する薬剤組成物
CN1211192A (zh) * 1995-09-18 1999-03-17 美国陆军医疗材料研究指挥部 生产非共价复合的多价蛋白体亚基疫苗的改进方法
JPH11513698A (ja) * 1995-10-25 1999-11-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 神経保護物質およびパーフルオロケミカルの注射剤
US5980945A (en) * 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
ES2118033B1 (es) * 1996-02-16 1999-07-01 Bial Ind Farmaceutica S A Formulacion farmaceutica antiinflamatoria.
SE9602280D0 (sv) * 1996-06-10 1996-06-10 Pharmatrix Ab Immunstimulerande lipidformulering
JP2001503735A (ja) * 1996-07-03 2001-03-21 ユニバーシティ オブ ピッツバーグ 親水性活性試薬のためのエマルジョン処方物
US7255877B2 (en) 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
US6465016B2 (en) * 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
WO1998007414A1 (en) * 1996-08-22 1998-02-26 Research Triangle Pharmaceuticals Ltd. Compositions comprising microparticles of water-insoluble substances and method for preparing same
SE9603667D0 (sv) * 1996-10-08 1996-10-08 Astra Ab Pharmaceutical compositions
US6071904A (en) * 1996-12-11 2000-06-06 Alcon Laboratories, Inc. Process for manufacturing ophthalmic suspensions
US7060277B2 (en) * 1996-12-30 2006-06-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Broad spectrum antagonists and vaccines directed against pyrogenic exotoxins
US6537561B1 (en) * 1997-02-27 2003-03-25 Nippon Shinyaku Co., Ltd. Fat emulsion for oral administration
US6143276A (en) * 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures
US5980912A (en) * 1997-03-25 1999-11-09 Zonagen, Inc. Chitosan induced immunopotentiation
SE9702776D0 (sv) * 1997-07-22 1997-07-22 Pharmacia & Upjohn Ab Method of preparing pharmaceutical compositions
US6306433B1 (en) 1997-08-12 2001-10-23 Pharmacia Ab Method of preparing pharmaceutical compositions
IL122084A (en) * 1997-10-31 1999-09-22 Lurident Ltd Formulation for personal care with mucoadhesive properties
US6270464B1 (en) 1998-06-22 2001-08-07 Artemis Medical, Inc. Biopsy localization method and device
GB9726916D0 (en) * 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
US6221378B1 (en) 1998-02-10 2001-04-24 Generex Pharmaceuticals Incorporated Mixed micellar delivery system and method of preparation
US6017545A (en) * 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation
US7070799B1 (en) * 1998-02-10 2006-07-04 Generex Pharmaceuticals, Inc. Method for administering insulin to the buccal region
ID25649A (id) 1998-03-09 2000-10-19 Takeda Chemical Industries Ltd Turunan-turunan sikloalkena, produksi serta penggunaannya
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
DE19819273A1 (de) * 1998-04-30 1999-11-11 Pharmatec International S Giul Pharmazeutische Ciclosporin-Formulierung mit verbesserten biopharmazeutischen Eigenschaften, erhöhter physikalischer Qualität und Stabilität sowie Verfahren zur Herstellung
DK1075276T3 (da) * 1998-05-07 2008-02-11 Corixa Corp Adjuvanssammensætning og fremgangsmåder til dens anvendelse
TWI241915B (en) 1998-05-11 2005-10-21 Ciba Sc Holding Ag A method of preparing a pharmaceutical end formulation using a nanodispersion
ES2216517T3 (es) 1998-05-29 2004-10-16 Skyepharma Canada Inc. Composiciones de microcapsulas termoprotegidas y procedimiento para su esterilizacion terminal con vapor.
EP1091762A1 (de) * 1998-07-02 2001-04-18 Genzyme Corporation Expression von transgenen in polarisierten zellen
DE19830375A1 (de) * 1998-07-08 2000-01-13 K D Pharma Bexbach Gmbh Mikroverkapselte ungesättigte Fettsäure oder Fettsäureverbindung oder Mischung aus Fettsäuren und/oder Fettsäureverbindungen
EP1105096B1 (de) 1998-08-19 2003-10-29 Skyepharma Canada Inc. Injizierbare wässerige propofoldispersionen
DE69929128T2 (de) * 1998-08-31 2006-06-29 Nipro Corp. Nährstoffinfusionspräparat
JP2007262088A (ja) * 1998-08-31 2007-10-11 Nipro Corp 栄養輸液製剤
ES2187201T3 (es) * 1998-10-14 2003-05-16 Cognis Deutschland Gmbh Empleo de esteroles y de esterolesteres a nanoescala.
IL143197A0 (en) 1998-11-20 2002-04-21 Rtp Pharma Inc Dispersible phospholipid stabilized microparticles
FR2787326B1 (fr) * 1998-12-17 2001-01-26 Oreal Nanoemulsion a base d'esters gras de glycerol, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
WO2000040219A1 (en) * 1998-12-30 2000-07-13 Dexcel Ltd. Dispersible concentrate for the delivery of cyclosporin
US7655252B2 (en) * 1999-04-28 2010-02-02 The Regents Of The University Of Michigan Antimicrobial nanoemulsion compositions and methods
US7767216B2 (en) * 1999-04-28 2010-08-03 The Regents Of The University Of Michigan Antimicrobial compositions and methods of use
US8232320B2 (en) * 1999-04-28 2012-07-31 The Regents Of The University Of Michigan Antimicrobial nanoemulsion compositions and methods
AU4917900A (en) * 1999-05-07 2000-11-21 Pharmasol Gmbh Lipid particles on the basis of mixtures of liquid and solid lipids and method for producing same
JP2003501376A (ja) * 1999-06-04 2003-01-14 スカイファーマ インコーポレーテッド 疎水性薬物の持続性放出のための油コア組成物
US7919113B2 (en) * 1999-12-30 2011-04-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Dispersible concentrate lipospheres for delivery of active agents
US6541025B1 (en) 1999-12-30 2003-04-01 Shear/Kershman Laboratories, Inc. Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
US6514523B1 (en) 2000-02-14 2003-02-04 Ottawa Heart Institute Research Corporation Carrier particles for drug delivery and process for preparation
EP1255561B1 (de) * 2000-02-15 2006-06-28 ID Biomedical Corporation of Quebec Proteasom-influenzavirus-impfstoffzusammensetzung
FR2805761B1 (fr) * 2000-03-02 2002-08-30 Mainelab Nanocapsules lipidiques, procede de preparation et utilisation comme medicament
US20010036463A1 (en) * 2000-03-09 2001-11-01 Compans Richard W. Transcutaneous immunization for large particulate antigens
US6861060B1 (en) 2000-04-21 2005-03-01 Elena Luriya Personal care formulations
DE10027948A1 (de) * 2000-06-08 2001-12-20 Henkel Kgaa Verfahren zur Herstellung von Nanopartikel-Suspensionen
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
DE10036871A1 (de) * 2000-07-28 2002-02-14 Pharmasol Gmbh Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe
US8586094B2 (en) 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
US6977085B2 (en) * 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US20030072807A1 (en) * 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
US7037528B2 (en) * 2000-12-22 2006-05-02 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US7193084B2 (en) * 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6951656B2 (en) * 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US20030096013A1 (en) * 2000-12-22 2003-05-22 Jane Werling Preparation of submicron sized particles with polymorph control
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US20040126900A1 (en) * 2001-04-13 2004-07-01 Barry Stephen E High affinity peptide- containing nanoparticles
EP2545937A1 (de) * 2001-06-05 2013-01-16 The Regents Of The University Of Michigan Nanoemulsionsimpfstoffe
US6676958B2 (en) * 2001-06-19 2004-01-13 Advanced Bioadjuvants, Llc Adjuvant composition for mucosal and injection delivered vaccines
WO2003009868A1 (en) * 2001-07-26 2003-02-06 Otago Innovation Limited Antigenic compositions
US7960416B2 (en) * 2001-08-03 2011-06-14 Takeda Pharmaceutical Company Limited Stable emulsion composition
US7125568B2 (en) 2001-08-23 2006-10-24 Sung Michael T Lipophilic drug compositions
CN1558755A (zh) 2001-09-26 2004-12-29 ���ع��ʹ�˾ 通过分散和除去溶剂或液相制备亚微米大小的纳米颗粒
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
IL145926A0 (en) * 2001-10-15 2002-07-25 Mor Research Applic Ltd Peptide epitopes of mimotopes useful in immunomodulation
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
US20060078618A1 (en) * 2001-12-11 2006-04-13 Constantinides Panayiotis P Lipid particles and suspensions and uses thereof
US7763663B2 (en) * 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
JP4549625B2 (ja) * 2002-01-05 2010-09-22 株式會社アモーレパシフィック 人参サポニン代謝産物を有効成分とする微細乳化粒子及びその製造方法、並びにこれを含有する皮膚老化防止用の化粧料組成物
KR20030065831A (ko) * 2002-02-01 2003-08-09 주식회사 태평양 사이클로스포린을 함유한 지속 방출형 약학적 조성물
US6899890B2 (en) * 2002-03-20 2005-05-31 Kv Pharmaceutical Company Bioadhesive drug delivery system
US6824763B2 (en) 2002-05-30 2004-11-30 Kimberly-Clark Worldwide, Inc. Anti-fungal powder having enhanced excipient properties
US8435942B2 (en) * 2002-05-31 2013-05-07 Transdermal Biotechnology, Inc. Methods for formulating stabilized insulin compositions
US20040018237A1 (en) * 2002-05-31 2004-01-29 Perricone Nicholas V. Topical drug delivery using phosphatidylcholine
HUP0202032A2 (hu) * 2002-06-19 2004-10-28 D. Endre Radics Nanoemulziós formulációban található bioaktív anyagok emberi szervezetbe való bevitele a szájüreg nyálkahártyáján keresztül, mechanikus pumpájú spray által.
US20040106785A1 (en) * 2002-07-25 2004-06-03 Micrologix Biotech Inc. Inhibitors of RNA dependent RNA polymerase and uses thereof
US20040213837A1 (en) * 2002-08-05 2004-10-28 Sankaram Mantripragada Oil-core compositions for the sustained release of hydrophobic drugs
US7459169B2 (en) * 2002-10-21 2008-12-02 Allvivo, Inc. Surface coating comprising bioactive compound
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
AU2003279493B2 (en) 2002-10-25 2009-08-20 Foamix Pharmaceuticals Ltd. Cosmetic and pharmaceutical foam
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
ITMI20022323A1 (it) * 2002-10-31 2004-05-01 Maria Rosa Gasco Composizioni farmaceutiche atte al trattamento di malattie oftalmiche.
US7255867B2 (en) * 2002-11-15 2007-08-14 Id Biomedical Corporation Of Quebec Vaccine
ES2376875T3 (es) * 2003-02-14 2012-03-20 Children's Hospital & Research Center At Oakland Vehículo de administración de fármacos lipofílicos y métodos de utilización del mismo
WO2004084859A2 (en) * 2003-03-21 2004-10-07 Nastech Pharmaceutical Company Inc. Nasal calcitonin formulations containing chlorobutanol
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
US20050208083A1 (en) * 2003-06-04 2005-09-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof
US7368537B2 (en) * 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
EP1667713A1 (de) * 2003-09-15 2006-06-14 ID Biomedical Corporation of Quebec Masern-untereinheit-vakzine
WO2005030172A1 (en) * 2003-09-24 2005-04-07 The Regents Of The University And Methods Antimicrobial nanoemulsion compositions and methods
EA200600877A1 (ru) * 2003-10-31 2006-12-29 Тева Фармасьютикал Индастриз, Лтд. Наночастицы для доставки лекарств
US20050196416A1 (en) * 2004-02-05 2005-09-08 Kipp James E. Dispersions prepared by use of self-stabilizing agents
CA2563544A1 (en) * 2004-04-19 2005-10-27 Centre National De La Recherche Scientifique (C.N.R.S.) Lung surfactant supplements
ITMI20041151A1 (it) * 2004-06-09 2004-09-09 Maria Rosa Gasco Nanoparticelle lipidiche come agenti veicolanti per acidi nucleici procedimento per la loro preparazione e loro uso
US7348802B2 (en) * 2004-06-15 2008-03-25 Stmicroelectronics Pvt. Ltd. Differential receiver
EP2332569A3 (de) * 2004-06-25 2011-09-14 ID Biomedical Corporation of Quebec Zusammensetzungen und Verfahren zur Behandlung von neurologischen Erkrankungen
KR20070052273A (ko) * 2004-06-30 2007-05-21 아이디 바이오메디컬 코포레이션 오브 퀘벡 코로나바이러스 감염의 치료를 위한 백신 조성물
US7871632B2 (en) 2004-07-12 2011-01-18 Adventrx Pharmaceuticals, Inc. Compositions for delivering highly water soluble drugs
US20060057216A1 (en) * 2004-09-15 2006-03-16 Salamone Joseph C Low-obscuration image transmitting particulate ocular therapeutic formulations
EP1674085A1 (de) * 2004-12-22 2006-06-28 Universite Libre De Bruxelles Feste Lipidteilchen als pharmazeutische annehmbare Füllstoffe oder Träger zur Inhalation
WO2006098966A2 (en) * 2005-03-09 2006-09-21 Combe Incorporated Stable mixed emulsions comprising semisolid dispersions of at least two discrete and distinctly different particle size ranges
FR2885538B1 (fr) * 2005-05-16 2007-08-10 Univ Claude Bernard Lyon Nouveau procede de preparation de particules lipidiques solides, mettant en oeuvre un reacteur membranaire
FR2887457B1 (fr) * 2005-06-23 2007-10-05 Fond Bettencourt Schueller Vaccination par ciblage transcutane
JP5368793B2 (ja) 2005-07-18 2013-12-18 ユニバーシティ オブ マサチューセッツ ロウエル ナノエマルジョンを製造および使用するための組成物および方法
US20070065390A1 (en) * 2005-09-19 2007-03-22 Eric Spengler Stable emulsion systems with high salt tolerance
CN101325944B (zh) * 2005-10-11 2013-01-16 耶路撒冷希伯来大学伊萨姆研究开发公司 用于鼻部给药的组合物
US7638142B2 (en) * 2005-10-12 2009-12-29 Vitamin Science, Inc. Therapeutic composition for the treatment of dry eye syndrome
EP1945340B1 (de) * 2005-11-10 2016-11-02 Karl-Heinz Parras Langzeitstabile dispersion und verfahren zur herstellung der dispersion
PT3144013T (pt) 2005-12-01 2019-02-07 Univ Massachusetts Lowell Nanoemulsões botulínicas
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
KR100792557B1 (ko) * 2006-04-05 2008-01-09 한남대학교 산학협력단 나노 캡슐화를 이용하여 제조된 지질 핵 및 고분자 쉘구조를 갖는 단백질 약물 전달용 나노 미립구
US9839685B2 (en) * 2006-04-13 2017-12-12 The Regents Of The University Of Michigan Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
US10138279B2 (en) 2006-04-13 2018-11-27 Regents Of The University Of Michigan Compositions and methods for Bacillus anthracis vaccination
US20080038295A1 (en) * 2006-04-13 2008-02-14 Regents Of The University Of Michigan Compositions and methods for orthopox virus vaccination
US20070243137A1 (en) * 2006-04-18 2007-10-18 Nanoprobes, Inc. Cell and sub-cell methods for imaging and therapy
PL2061427T3 (pl) * 2006-09-15 2011-12-30 Echo Pharmaceuticals Bv Granulat zawierający substancję farmaceutycznie aktywną i emulgator oraz sposób jego wytwarzania
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
AU2007353340A1 (en) 2006-12-01 2008-11-20 Anterios, Inc. Peptide nanoparticles and uses therefor
WO2008070538A2 (en) 2006-12-01 2008-06-12 Anterios, Inc. Micellar nanoparticles comprising botulinum toxin
MX2009008248A (es) * 2007-02-07 2009-08-12 Sigma Tau Ind Farmaceuti Antigenos recombinantes de citomegalovirus humano.
CA2680206C (en) * 2007-03-05 2015-07-07 Washington University Nanoparticle delivery systems for membrane-integrating peptides
ES2542058T3 (es) * 2007-03-30 2015-07-30 Particle Sciences, Inc. Formulaciones en forma de partículas y usos de las mismas
US8747872B2 (en) 2007-05-02 2014-06-10 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
WO2008135828A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
WO2008135855A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
US20080292663A1 (en) * 2007-05-22 2008-11-27 Gerber Jay D Adjuvant compositions and methods for delivering vaccines
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
CA2688415C (en) 2007-05-31 2015-11-10 Anterios, Inc. Nucleic acid nanoparticles and uses therefor
WO2008149230A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
WO2008149192A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
WO2009042114A2 (en) 2007-09-21 2009-04-02 The Johns Hopkins University Phenazine derivatives and uses thereof
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
EP2240162A4 (de) 2007-12-06 2013-10-09 Bend Res Inc Nanoteilchen mit einem nicht-ionisierbaren polymer und einem amin-funktionalisierten methacrylat-copolymer
US9724362B2 (en) 2007-12-06 2017-08-08 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
US8518376B2 (en) 2007-12-07 2013-08-27 Foamix Ltd. Oil-based foamable carriers and formulations
WO2009090495A2 (en) 2007-12-07 2009-07-23 Foamix Ltd. Oil and liquid silicone foamable carriers and formulations
US8906855B2 (en) 2007-12-22 2014-12-09 Vivacelle Bio, Inc. Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries
US8063020B2 (en) * 2007-12-22 2011-11-22 Simpkins Cuthbert O Resuscitation fluid
US8618056B2 (en) 2007-12-22 2013-12-31 Cuthbert O. Simpkins Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries
EP2242476A2 (de) 2008-01-14 2010-10-27 Foamix Ltd. Aufschäumbare pharmazeutische poloxamer-zusammensetzungen mit wirkstoffen und/oder therapeutischen zellen und verwendungen
WO2009143175A2 (en) * 2008-05-19 2009-11-26 Children's Medical Center Corporation Sensory-specific local anesthesia and prolonged duration local anesthesia
US8658699B2 (en) * 2008-05-19 2014-02-25 Massachusetts Institute Of Technology Chemical permeation enhancers enhance nerve blockade by toxins
CA2725329C (en) 2008-05-23 2013-10-01 The Regents Of The University Of Michigan Nanoemulsion vaccines
US8268796B2 (en) 2008-06-27 2012-09-18 Children's Hospital & Research Center At Oakland Lipophilic nucleic acid delivery vehicle and methods of use thereof
DE102008045152A1 (de) * 2008-07-09 2010-01-14 Universität Duisburg-Essen Künstliche Sauerstoffträger und ihre Verwendung
JP5713897B2 (ja) * 2008-07-16 2015-05-07 エボニック コーポレイションＥｖｏｎｉｋ Ｃｏｒｐｏｒａｔｉｏｎ 生理活性ペプチドを含有する微粒子を調製するためのプロセス
JP5722782B2 (ja) 2008-09-26 2015-05-27 ナノバイオ コーポレーション ナノエマルジョン治療用組成物及びその使用方法
US8309107B2 (en) * 2008-10-06 2012-11-13 Banner Pharmacaps, Inc. Stable solutions of orlistat for pharmaceutical dosage forms
WO2010057197A1 (en) 2008-11-17 2010-05-20 The Regents Of The University Of Michigan Cancer vaccine compositions and methods of using the same
FR2939699B1 (fr) 2008-12-12 2011-05-06 Univ Angers Procede de preparation de nanoparticules lipidiques
EP2391341A4 (de) * 2009-01-30 2012-05-09 Cuthbert O Simpkins Wiederbelebungsflüssigkeit
US8952152B2 (en) 2009-03-24 2015-02-10 Proteus S.A. Methods for purifying phycotoxins, pharmaceutical compositions containing purified phycotoxins, and methods of use thereof
EP2419392A4 (de) * 2009-04-15 2013-02-27 Oxygen Biotherapeutics Inc Perfluorkohlenstoffemulsionen
WO2010125470A2 (en) 2009-04-28 2010-11-04 Foamix Ltd. Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
WO2010132833A1 (en) * 2009-05-14 2010-11-18 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
CN101579291B (zh) * 2009-05-20 2011-06-15 清华大学 一种白藜芦醇磷脂复合物纳米乳液及其制备方法与应用
BRPI1014031A2 (pt) * 2009-06-16 2018-02-20 Univ Michigan Regents vacinas de nanoemulsão
WO2011013009A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
CA2769677A1 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
WO2011017520A1 (en) 2009-08-05 2011-02-10 Wake Forest University Health Sciences Compositions and methods for inducing apoptosis in prostate cancer cells
MX359879B (es) 2009-10-02 2018-10-12 Foamix Pharmaceuticals Ltd Composiciones tópicas de tetraciclina.
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US8174881B2 (en) 2009-11-24 2012-05-08 Micron Technology, Inc. Techniques for reducing disturbance in a semiconductor device
CN102933200B (zh) * 2009-12-18 2015-11-25 莱迪杜德制药公司 包含磷脂的单相凝胶组合物
FR2956320B1 (fr) * 2010-02-17 2013-12-20 Commissariat Energie Atomique Nanoemulsion pour la delivrance d'au moins deux agents d'interet
US20110229516A1 (en) * 2010-03-18 2011-09-22 The Clorox Company Adjuvant phase inversion concentrated nanoemulsion compositions
PT2550020E (pt) * 2010-03-24 2015-10-20 Medesis Pharma Microemulsão de micelas reversas compreendendo iões metálicos e sua utilização
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
TWI540319B (zh) 2010-03-29 2016-07-01 中央研究院 以細胞質譜分析定量細胞所攝入之奈米/微米粒子
CN102232932B (zh) * 2010-04-27 2013-06-05 重庆莱美药业股份有限公司 果胶-阿霉素轭合物的冻干制剂及制备方法
US10758630B2 (en) 2010-08-13 2020-09-01 The Johns Hopkins University Topical compositions and methods of detection and treatment
US8658676B2 (en) * 2010-10-12 2014-02-25 The Medicines Company Clevidipine emulsion formulations containing antimicrobial agents
JP2014509311A (ja) * 2011-01-05 2014-04-17 ザ レジェンツ オブ ザ ユニヴァーシティー オブ カリフォルニア 低キャビテーション閾値の音響応答性粒子
US8668937B2 (en) 2011-03-17 2014-03-11 Transdermal Biotechnology, Inc. Topical nitric oxide systems and methods of use thereof
DK2691530T3 (en) 2011-06-10 2018-05-22 Univ Oregon Health & Science CMV GLYCOPROTEIN AND RECOMBINANT VECTORS
EP2723452A2 (de) 2011-06-22 2014-04-30 Vyome Biosciences Pvt Ltd Konjugatbasierte antimykotische und antibakterielle prodrugs
EP2568289A3 (de) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunselektion von rekombinantem vesikulärem Stomatitisvirus mit Expression von HIV-1-Proteinen durch Breitbandneutralisierungs-Antikörper
KR101803902B1 (ko) * 2011-09-16 2017-12-04 (주)아모레퍼시픽 세라마이드를 포함하는 피부 외용제 조성물
US8883220B2 (en) * 2011-09-16 2014-11-11 Nanocare Technologies, Inc. Compositions of jasmonate compounds
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
WO2013082503A1 (en) * 2011-12-01 2013-06-06 Flow Pharma, Inc. Peptide particle formulation
EP4218808A3 (de) 2012-03-12 2023-08-09 Advanced BioAdjuvants, LLC Adjuvans- und impfstoffzusammensetzungen
TWI483747B (zh) * 2012-05-29 2015-05-11 Univ Nat Chiao Tung 口服式藥物載體及其製備方法
EP2679596B1 (de) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 Env-proteinvariante
US8871261B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Cancer treatments and compositions for use thereof
US8871262B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Compositions and methods for treatment of osteoporosis and other indications
US8871255B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment of skin and soft tissue infection with nitric oxide
US8871260B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and compositions for muscular and neuromuscular diseases
US8871256B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and systems for treatment of inflammatory diseases with nitric oxide
US8871257B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery
US8871254B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US8871258B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment and prevention of learning and memory disorders
US8871259B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Techniques and systems for treatment of neuropathic pain and other indications
US20140234433A1 (en) * 2013-02-15 2014-08-21 Nicholas V. Perricone Topical Composition for Stimulating Epidermis and Dermis Layers of the Skin
ES2819234T3 (es) 2013-02-25 2021-04-15 Particle Sciences Inc Formulaciones de partículas para la administración de agonistas de TLR y antígenos
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US20140271937A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9724419B2 (en) 2013-03-13 2017-08-08 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US20140271938A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9750787B2 (en) 2013-03-13 2017-09-05 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US20140271731A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
EP2968225B1 (de) 2013-03-15 2019-02-20 The Children's Medical Center Corporation Neosaxitoxinkombinationsformulierungen für verlängerte lokalanästhesie
FR3008900B1 (fr) * 2013-07-25 2018-03-30 Centre Nat Rech Scient Nanoparticules lipidiques multicompartimentees
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
CA3002989C (en) 2013-10-14 2021-03-16 Nanosphere Health Sciences, Llc Nanoparticle compositions and methods as carriers of nutraceutical factors across cell membranes and biological barriers
PL3060041T3 (pl) 2013-10-25 2021-08-02 Insmed Incorporated Związki prostacykliny
IL246456B2 (en) 2013-12-31 2024-06-01 Access To Advanced Health Inst Formulations will be assembled into a single vial
US9895311B2 (en) * 2014-09-25 2018-02-20 Pharmiva Ab Foam-forming compositions and methods for delivering an active to a body cavity
ES2873873T3 (es) 2014-11-18 2021-11-04 Insmed Inc Métodos de fabricación de treprostinilo y profármacos derivados de treprostinilo
US20160151285A1 (en) * 2014-11-28 2016-06-02 University Of Malaya Method to produce slow release delivery carrier lipid nanoparticles of different log p value
US11707436B2 (en) 2014-12-15 2023-07-25 Nanosphere Health Sciences Inc. Methods of treating inflammatory disorders and global inflammation with compositions comprising phospholipid nanoparticle encapsulations of NSAIDS
CA2971870A1 (en) 2014-12-31 2016-07-07 Nanocare Technologies, Inc. Jasmonate derivatives and compositions thereof
WO2017054071A1 (en) * 2015-01-21 2017-04-06 Willinsky Michael Composition and methods to improve stability, dosing, pharmacodynamics and product shelf life of endocannabinoids, phytocannabinoids and synthetic cannabinoids delivered by nasal inhaler
CA2979184C (en) 2015-03-10 2020-09-08 Nanosphere Health Sciences, Llc Lipid nanoparticle compositions and methods as carriers of cannabinoids in standardized precision-metered dosage forms
EP3069730A3 (de) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
US9763892B2 (en) 2015-06-01 2017-09-19 Autotelic Llc Immediate release phospholipid-coated therapeutic agent nanoparticles and related methods
EP3362042A1 (de) * 2015-10-16 2018-08-22 Marinus Pharmaceuticals, Inc. Injizierbare neurosteroidformulierungen mit nanopartikeln
EP3468539A4 (de) 2016-06-13 2020-01-15 Ascendia Pharmaceuticals, LLC Parenterale verabreichung mit verzögerter freisetzung von carvedilol-dispersionssystemen
CA2978573A1 (en) 2016-09-08 2018-03-08 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
JP2019535829A (ja) 2016-11-21 2019-12-12 エイリオン セラピューティクス， インコーポレイテッド 大型薬剤の経皮送達
CA3053158A1 (en) * 2017-02-15 2018-08-23 Molecular Infusions, Llc Formulations
US11135166B2 (en) 2017-05-23 2021-10-05 Pharmiva Ab Foam-forming compositions for delivering an active to a body cavity
TWI719263B (zh) * 2017-10-27 2021-02-21 財團法人國家衛生研究院 用於鼻黏膜之奈米級乳液免疫載劑及其製備方法
KR102052912B1 (ko) * 2018-03-30 2019-12-06 중앙대학교 산학협력단 산소를 함유하는 나노 버블의 제조 방법, 나노 버블 및 이를 포함하는 약물 전달체
EP3823595A1 (de) 2018-07-18 2021-05-26 Glatt Gmbh Cannabinoidformulierungen mit verlängerter freisetzung
US20220249369A1 (en) * 2018-09-19 2022-08-11 Georgia Tech Research Corporation Biological bits as computable elements within living systems
US12458595B2 (en) * 2018-10-15 2025-11-04 Henry J. Smith Thermally stabilized nanoemulsion
SG11202106144VA (en) * 2018-12-11 2021-07-29 Disruption Labs Inc Compositions for the delivery of therapeutic agents and methods of use and making thereof
EP3937912A4 (de) * 2019-03-13 2022-12-21 Ulagaraj Selvaraj Stabilisierte feste nanopartikelformulierungen von cannabinoiden und cannabinoid-analogen mit reduzierter ostwald-reifung zur oralen, inhalativen, nasalen und parenteralen wirkstoffabgabe
TR201905678A2 (tr) * 2019-04-16 2020-11-23 Univ Istanbul Medipol Kurkumi̇n ve pi̇peri̇n doğal bi̇leşenleri̇ni̇ i̇hti̇va eden kati li̇pi̇t emulsi̇yonlarinin tedavi̇ amaçli uygulamalari
JP7455144B2 (ja) 2019-04-29 2024-03-25 インスメッド インコーポレイテッド トレプロスチニルプロドラッグの乾燥粉末組成物およびその使用方法
US20200352191A1 (en) * 2019-05-06 2020-11-12 Karl Lonsbery Edible formulations and uses thereof
AU2020417820A1 (en) * 2020-01-02 2022-08-18 Spoke Sciences, Inc. Systems and methods for generating homogenous mixtures of brewed beverages and active ingredients
US12576039B2 (en) 2020-05-18 2026-03-17 Max Biology Co. Ltd. Lipid-polymer compositions and methods of use
WO2022026796A1 (en) * 2020-07-31 2022-02-03 Altaire Pharmaceuticals, Inc. Ophthalmic compositions for delivering meibum-like materials
US11058637B1 (en) * 2020-11-25 2021-07-13 King Abdulaziz University Surface-modified emulsomes for intranasal delivery of drugs
US20250032368A1 (en) * 2021-12-16 2025-01-30 Dynabio Biomed Technology Co., Ltd. Plant oil preparation and preparation method therefor
WO2024218751A1 (en) * 2023-04-21 2024-10-24 Disruption Labs Inc. Oil free lipid nanoparticles for stabilizing hydrophobic agents and methods of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880635B1 (en) * 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US5023271A (en) * 1985-08-13 1991-06-11 California Biotechnology Inc. Pharmaceutical microemulsions
US4987154A (en) * 1986-01-14 1991-01-22 Alliance Pharmaceutical Corp. Biocompatible, stable and concentrated fluorocarbon emulsions for contrast enhancement and oxygen transport in internal animal use
IL88076A (en) * 1987-10-28 1993-01-14 Nippon Shinyaku Co Ltd Fat emulsions as drug carriers
US5171737A (en) * 1989-03-03 1992-12-15 The Liposome Company, Inc. Emulsions
US5188837A (en) * 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
EP0502119B1 (de) * 1989-11-13 1996-01-31 Scios Nova, Inc. Liposphären zur kontrollierten substanzabgabe
FR2660193B1 (fr) * 1990-04-03 1994-11-04 Philippe Maincent Produit opthalmique comportant des nanocapsules, son procede de preparation et utilisation des nanocapsules.
US5306508A (en) * 1990-06-22 1994-04-26 The Regents Of The University Of California Red blood cell surrogate
AU658608B2 (en) * 1991-03-25 1995-04-27 Astellas Pharma Europe B.V. Topical preparation containing a suspension of solid lipid particles
US5284663A (en) * 1991-07-23 1994-02-08 Temple University Salt film encapsulated perfluorocarbons
DE4131562A1 (de) * 1991-09-18 1993-03-25 Medac Klinische Spezialpraep Arzneistofftraeger aus festen lipidteilchen-feste lipidnanosphaeren (sln)
WO1993015736A1 (en) * 1992-02-18 1993-08-19 Pharmos Corp. Dry compositions for preparing submicron emulsions
US5302401A (en) * 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles

Also Published As

Publication number Publication date
CA2162993C (en) 2004-03-30
JP3626184B2 (ja) 2005-03-02
US5716637A (en) 1998-02-10
AU676921B2 (en) 1997-03-27
IL109641A0 (en) 1994-08-26
AU6916494A (en) 1994-12-12
CA2162993A1 (en) 1994-11-24
WO1994026255A1 (en) 1994-11-24
DE69426418T2 (de) 2001-05-10
US5576016A (en) 1996-11-19
WO1994026252A1 (en) 1994-11-24
EP0702552A4 (de) 1997-05-21
DE69426418D1 (de) 2001-01-18
JPH08511245A (ja) 1996-11-26
SG106029A1 (en) 2004-09-30
US5662932A (en) 1997-09-02
EP0702552B1 (de) 2000-12-13
EP0702552A1 (de) 1996-03-27
IL109641A (en) 2000-02-29
AU6948094A (en) 1994-12-12

Similar Documents

Publication Publication Date Title
ATE198040T1 (de) Feste fettnanoemulsionen als wirkstoffabgabevehikel
KR960033471A (ko) 나노현탁액용 제약 담체
KR950703954A (ko) 외상 손상과 관련된 신경학적 병변의 치료에서 릴루졸의 적용(application of riluzole in the treatment of neurological lesions related to traumatic injuries)
NO304889B1 (no) Imidazopyridiner og deres anvendelse ved fremstilling av legemidler til behandling av mave-tarm-sykdommer
KR950031069A (ko) 골손실의 억제 및 혈청 콜레스테롤의 강하 방법
JPH08208486A (ja) スタウロスポリン誘導体の静脈内投与のための医薬組成物
AU677279B2 (en) Application of carbamazepine and oxcarbazepine in the treatment of Parkinson's disease and Parkinsonian syndromes
GR3023266T3 (en) 1,2,3,5,6,7,8,8a-OCTAHYDRO-5,5,8a-TRIMETHYL-(8a-g(b))-6-ISOQUINOLINEAMINE DERIVATIVES, PREPARATION METHOD THEREFOR AND THERAPEUTICAL USE THEREOF.
ATE152448T1 (de) Heterozyklische alkylamide, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
AU4500793A (en) Derivatives in the vitamin d series modified at the 20 position, a method of preparing such derivatives, intermediates used in this method, pharmaceutical preparations containing the derivatives and their use in the preparation of drugs
AU2797695A (en) Thiazolidine derivatives, their preparation and drugs containing same
ES2124905T3 (es) Esteroides antiglucocorticoides destinados al tratamiento de trastornos de ansiedad.
TR200101163T2 (tr) Safra suyu ikameli fenil-alkenoilguanidinler, üretim yöntemleri, kullanımları
IL124091A (en) Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for the preparation of pharmaceutical compositions for the treatment of amyotrophic lateral sclerosis and pharmaceutical compositions containing it
Williams et al. Interleukin‐1β (IL‐1β) inhibition: a possible mechanism for the anti‐inflammatory potency of liposomally conjugated methotrexate formulations in arthritis
SG67287A1 (en) New derivatives of physostigmine their use and pharmaceutical formulation containing them
ATE312599T1 (de) Impfstoffe zur oralen verwendung die liposomen sowie eine nukleinsäure enthalten
FR2773798B1 (fr) Nouveaux composes tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
IL112668A (en) 4-Amino 6-substituted mycophenolic acid and derivatives thereof their preparation and pharmaceutical compositions containing them
Nishikawa et al. Combined treatment of tardive dyskinesia with clonidine and neuroleptics: a follow-up study of three cases for three years
O'Hanlon Discussion of “Medications and the Safety of the Older Driver” by Ray et al.
ES2137665T3 (es) Nuevos derivados de piridina o piridazina, procedimientos para su preparacion, y medicamentos que contienen estos compuestos.
DE59307796D1 (de) Entzündungshemmende makrolactame (cyclamenol)
ATE409041T1 (de) Weibliche verhütungmethode und pharmazeutische zubereitungen die für eine solche methode geeignet sind
DE59403892D1 (de) DIBENZ[b,e]OXEPINDERIVATE, VERFAHREN ZU IHRER HERSTELLUNG UND DIESE ENTHALTENDE ARZNEIMITTEL

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee